



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

732.ALLOGENEIC TRANSPLANTATION: DISEASE RESPONSE AND COMPARATIVE TREATMENT STUDIES

Impact of Multiple Minor Histocompatibility Antigen Differences on Graft-Versus-Host Disease and Relapse Risk in Pediatric Allogeneic Hematopoietic Cell Transplantation Recipients

Christian Mueller¹, Malik Alawi¹, Juergen Loeffler², Michael Bonin³, Andreas Schreiber³, Hermann Kreyenberg⁴, Verena Wiegering, MD⁵, Matthias Woelfl⁵, Ignazio Caruana, PhD⁵, Paul G. Schlegel, MD⁵, Matthias Eyrich, MD⁵

¹University Medical Center Hamburg-Eppendorf, Hamburg, Germany

²Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany

³IMGM Laboratories GmbH, Martinsried, Germany

⁴Universitätsklinikum Frankfurt, Frankfurt am Main, Germany

⁵Department of Pediatrics, University Hospital Würzburg, Würzburg, Germany

BACKGROUND Success of allogeneic hematopoietic cell transplantation (alloHCT) is sharpened by alloreactivity, i.e. the ability of donor T-cells to recognize particular recipient motifs as non-self and get activated. Donor T-cells recognizing recipient tissue can cause harmful graft-versus-host disease (GvHD) while activity against leukemic blasts can protect against relapse (GvL). In HLA-matched alloHCT, alloreactivity is driven by subtle nonpathogenic variants in natural proteins, so-called minor histocompatibility antigens (miHAGs), however, not all variants are immunogenic. **METHODS** To analyze the impact of miHAGs-differences on alloHCT outcomes, we selected a purely pediatric cohort of 102 HLA-matched allo HCTs transplanted between 2003 and 2017. Panel sequencing of 46 validated miHAGs was performed using Illumina MiSeq, only variants in the graft-versus-host direction were considered. **RESULTS** In a logistic regression model for the whole cohort acute GvHD incidence was significantly dependent on the proportion of miHAG mismatches (all genes) with an 95%-CI 1.0263-1.1998, $p=.01$ and an odds ratio of 1.1066. From all variants tested, only mismatches in TRIM42 were significant as a predictor with a FDR $<.05$. Furthermore, proportion of mismatches was a predictor of all-cause mortality. Risk of relapse was evaluated by regression analysis for competing risks: proportion of miHAG mismatches failed to be predictive for relapse ($p=.37$). However, looking at patients with acute lymphoblastic leukemia (ALL) only ($n=36$), mismatches in hematopoiesis-restricted genes protected from relapse (95%-CI 1.0016-1.0712, $p=.04$, hazard ratio 1.0358). **CONCLUSION** Thus, in children GvHD and mortality seem to be related to the overall number of miHAG-differences whereas variants in hematopoiesis-restricted genes protect from ALL relapse. These data implicate that selection of TCRs with a specificity for hematopoietic miHAGs could be a way to improve GvL effect without increasing the risk of Gvhd.

Disclosures Eyrich: Vertex: Membership on an entity's Board of Directors or advisory committees.

<https://doi.org/10.1182/blood-2023-188511>